These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32854676)

  • 1. Silodosin improves functional consequences of lower urinary tract obstruction secondary to benign prostate hypertrophy, a proof of concept study in the spontaneously hypertensive rat supplemented with testosterone.
    Assaly R; Faugeroux J; Laurin M; Compagnie S; Alexandre L; Giuliano F; Behr-Roussel D
    BMC Urol; 2020 Aug; 20(1):132. PubMed ID: 32854676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
    Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
    PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of silodosin and naftopidil in the treatment of bladder dysfunction in the spontaneously hypertensive rat.
    Saito M; Shimizu S; Ohmasa F; Oikawa R; Tsounapi P; Dimitriadis F; Kinoshita Y; Satoh K
    Neurourol Urodyn; 2013 Apr; 32(4):393-8. PubMed ID: 22907830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
    Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
    Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.
    Villa L; Capogrosso P; Capitanio U; Martini A; Briganti A; Salonia A; Montorsi F
    Adv Ther; 2019 Jan; 36(1):1-18. PubMed ID: 30523608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study.
    Fusco F; Creta M; Longo N; Persico F; Franco M; Mirone V
    BMC Urol; 2018 Mar; 18(1):12. PubMed ID: 29502524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat.
    Inoue S; Saito M; Tsounapi P; Dimitriadis F; Ohmasa F; Kinoshita Y; Satoh K; Takenaka A
    BJU Int; 2012 Jul; 110(2 Pt 2):E118-24. PubMed ID: 22146017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFFICACY OF SILODOSIN (UROREC®) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: THE MAXIMUM DECREASE OF BLADDER OUTLET OBSTRUCTION INDEX.
    Khamzin A; Frolov R
    Georgian Med News; 2018 Mar; (276):18-23. PubMed ID: 29697376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males.
    Steers WD; Clemow DB; Persson K; Sherer TB; Andersson KE; Tuttle JB
    Exp Physiol; 1999 Jan; 84(1):137-47. PubMed ID: 10081714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of silodosin, a selective alpha-1A adrenoceptor antagonist, on erectile function in a rat model of partial bladder outlet obstruction.
    Bastaskın T; Kaya E; Ozakca I; Yilmaz D; Bayatlı N; Akdemir AO; Gur S
    Neurourol Urodyn; 2017 Mar; 36(3):597-603. PubMed ID: 27061103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of silodosin, a selective α(1A)-adrenoceptor antagonist, on voiding behavior and bladder blood flow in a rat model of bladder outlet obstruction.
    Goi Y; Tomiyama Y; Yokoyama A; Tatemichi S; Maruyama K; Kobayashi M; Yamaguchi O
    Eur J Pharmacol; 2015 Oct; 764():489-496. PubMed ID: 26189024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.
    Shimizu N; Minami T; Sugimoto K; Saito Y; Yamamoto Y; Hayashi T; Tsuji H; Nozawa M; Yoshimura K; Ishii T; Uemura H; Nakamatsu K
    World J Urol; 2014 Dec; 32(6):1423-32. PubMed ID: 24435207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.